Called Strike 3 For Bristol-Myers Squibb: What This Says For Gilead And Its Competitors In The Hep C Market
- Bristol-Myers Squibb halts NDA for its NS3/4A protease inhibitor, asunaprevir.
- BMY shows weakness that its current regimen of daclatasvir and asunaprevir is inferior to Gilead's Harvoni in HCV genotype 1b patients.
- Gilead's Harvoni is leading the show in HCV. Can anyone catch them?